P1171: REFLECT: PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ-RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA

P1171: REFLECT: PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ-RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA

Bibliographic Details
Main Authors:	M. Welslau, B. Kubuschok, J. Topaly, B. Otremba, T. Wolff, G. Bryn
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847548.21824.f5

Similar Items

REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma
by: Manfred Welslau, et al.
Published: (2023-06-01)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
by: Giulia Bega, et al.
Published: (2021-12-01)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
by: Michael Herold, et al.
Published: (2022-03-01)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Published: (2022-06-01)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
by: Benoit Tessoulin, et al.
Published: (2023-08-01)

Abfallprobleme bei Sandoz
by: Max Heusser
Published: (1990-06-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
by: J.-F. Bai, et al.
Published: (2022-06-01)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
by: Koh Ki-Ryang, et al.
Published: (2009-08-01)

Tekstualne trudności opowiadania o Gedeonie (Sdz 6–8)
by: Antoni Długosz
Published: (1980-10-01)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
by: William Townsend, et al.
Published: (2023-07-01)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
by: A. Haujir, et al.
Published: (2022-06-01)

Evaluasi Strategi PT Sandoz Indonesia
by: , Rina Kusumawati, et al.
Published: (2013)

Adolf Sandoz, an Orientalist Painter in Algeria
by: Wójcik, Agata
Published: (2017-04-01)

RTX-Toxins
by: Roland Benz
Published: (2020-05-01)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
by: Vít Procházka, et al.
Published: (2020-07-01)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)
by: Catherine Thieblemont, et al.
Published: (2023-08-01)

Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients
by: Shokhan Mohammad Mustafa, et al.
Published: (2021-01-01)

PB2307: PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB COMBINED WITH CHOP IN CHINESE PATIENTS WITH UNTREATED CD20-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA: A RANDOMIZED TRIAL
by: Yan Gao, et al.
Published: (2023-08-01)

Adolf Sandoz - malarz orientalista w Algierii
by: Wójcik, Agata
Published: (2017-04-01)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
by: Paolo Strati, et al.
Published: (2023-08-01)

S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY
by: W. Townsend, et al.
Published: (2022-06-01)

P1192: ANTI-PD-1 ANTIBODY (TISLELIZUMAB) COMBINED WITH R-CHOP FOR THE TREATMENT OF PREVIOUSLY UNTREATED PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A PROSPENTIVE PHASE II STUDY
by: Wu Mei, et al.
Published: (2023-08-01)

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
by: Carsten Hirt, et al.
Published: (2021-07-01)

Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting
by: Ana Muntañola, et al.
Published: (2023-02-01)

<i>Kingella kingae</i> RtxA Cytotoxin in the Context of Other RTX Toxins
by: Katerina Filipi, et al.
Published: (2022-02-01)

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
by: Silvana Novelli, et al.
Published: (2023-08-01)

William II of Hauteville (1171–1189)
by: Mirko Vagnoni
Published: (2021-07-01)

Ayyubis and early Mamluks 1171-1270 [slaid]
Published: (1977)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
by: LI Caixia, et al.
Published: (2023-08-01)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
by: O. Mompel, et al.
Published: (2022-06-01)

Le fantastique de Maurice Sandoz : Le cas du "Labyrinthe"
by: Pierre Van Cutsem
Published: (2023-10-01)

PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9)
by: J. Westin, et al.
Published: (2022-06-01)

Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
by: Murat Özbalak, et al.
Published: (2022-11-01)

Rapid Purification of Endotoxin-Free RTX Toxins
by: Ondrej Stanek, et al.
Published: (2019-06-01)

Short-term Clinical Outcome of Previously Untreated and Treated Schizophrenia and Impact of Duration of Untreated Psychosis
by: Priyanka Bansal, et al.
Published: (2023-07-01)

P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE
by: Michael Roost Clausen, et al.
Published: (2023-08-01)

Results of CHOP chemotherapy for diffuse large B-cell lymphoma
by: A.E. Hallack Neto, et al.
Published: (2006-10-01)